Comparative Pharmacology
Head-to-head clinical analysis: AVYCAZ versus DOCIVYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVYCAZ versus DOCIVYX.
AVYCAZ vs DOCIVYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
Docivyx is a docetaxel formulation; it binds to tubulin, promoting assembly of microtubules and inhibiting depolymerization, leading to cell cycle arrest and apoptosis.
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
75 mg/m2 intravenously over 1 hour every 3 weeks.
None Documented
None Documented
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., CrCl <50 mL/min requires dose adjustment).
Terminal elimination half-life is 24-48 hours; prolonged with hepatic impairment.
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
Primarily hepatic metabolism followed by biliary excretion; <10% excreted unchanged in urine.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic